

# United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

ATTORNEY DOCKET NO. CONFIRMATION NO. APPLICATION NO. FILING DATE FIRST NAMED INVENTOR Ramakrishna S. Madabhushi 4221C6 4791 12/28/2001 10/040,539 **EXAMINER** 04/27/2004 22896 7590 MILA KASAN, PATENT DEPT. REDDICK, MARIE L APPLIED BIOSYSTEMS **ART UNIT** PAPER NUMBER 850 LINCOLN CENTRE DRIVE FOSTER CITY, CA 94404 1713

DATE MAILED: 04/27/2004

Please find below and/or attached an Office communication concerning this application or proceeding.

	Application No.	Applicant(s)	
Office Action Summary	10/040,539	MADABHUSHI ET	AL.
	Examiner	Art Unit	
	Judy M. Reddick	1713	duela
The MAILING DATE of this communication app Period for Reply		/	dress/
A SHORTENED STATUTORY PERIOD FOR REPLY THE MAILING DATE OF THIS COMMUNICATION.  - Extensions of time may be available under the provisions of 37 CFR 1.13 after SIX (6) MONTHS from the mailing date of this communication.  - If the period for reply specified above is less than thirty (30) days, a reply if NO period for reply is specified above, the maximum statutory period versiliure to reply within the set or extended period for reply will, by statute Any reply received by the Office later than three months after the mailing earned patent term adjustment. See 37 CFR 1.704(b).	36(a). In no event, however, may a reply be to within the statutory minimum of thirty (30) day will apply and will expire SIX (6) MONTHS from a cause the application to become ABANDON	imely filed hys will be considered timely in the mailing date of this co ED (35 U.S.C. § 133).	y. ommunication.
Status			
1) Responsive to communication(s) filed on 12/28 2a) This action is <b>FINAL</b> . 2b) This 3) Since this application is in condition for alloward closed in accordance with the practice under E	action is non-final. nce except for formal matters, p	rosecution as to the	e merits is
Disposition of Claims	•		
<ul> <li>4) ☐ Claim(s) 22-29 is/are pending in the application 4a) Of the above claim(s) is/are withdray</li> <li>5) ☐ Claim(s) is/are allowed.</li> <li>6) ☒ Claim(s) 22-29 is/are rejected.</li> <li>7) ☐ Claim(s) is/are objected to.</li> <li>8) ☐ Claim(s) are subject to restriction and/or</li> </ul>	wn from consideration.		
Application Papers			
9)☐ The specification is objected to by the Examine 10)☒ The drawing(s) filed on 28 December 2001 is/a Applicant may not request that any objection to the Replacement drawing sheet(s) including the correct 11)☐ The oath or declaration is objected to by the Examine 100.☐ The oath or declaration is objected to by the Examine 110.☐ The oath or declaration is objecte	are: a) accepted or b) objeed or b) objeed drawing(s) be held in abeyance. Stion is required if the drawing(s) is c	ee 37 CFR 1.85(a). objected to. See 37 C	FR 1.121(d).
Priority under 35 U.S.C. § 119		•	
12) Acknowledgment is made of a claim for foreign a) All b) Some * c) None of:  1. Certified copies of the priority document 2. Certified copies of the priority document 3. Copies of the certified copies of the priority application from the International Burea * See the attached detailed Office action for a list	ts have been received. ts have been received in Applica ority documents have been recei au (PCT Rule 17.2(a)).	ation No ved in this National	Stage
Attachment(s)  1) Notice of References Cited (PTO-892)	4) Interview Summa	•	
<ul> <li>2) Notice of Draftsperson's Patent Drawing Review (PTO-948)</li> <li>3) Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08)</li> <li>Paper No(s)/Mail Date <u>04/08/02</u>.</li> </ul>	Paper No(s)/Mail  5) Notice of Informa  6) Other:	Date I Patent Application (PT	O-152)

Application/Control Number: 10/040,539

Art Unit: 1713

í.

#### **DETAILED ACTION**

#### **Information Disclosure Statement**

1. The information disclosure statement filed 04/08/02 has been considered and scanned into the application file.

#### **Drawings**

2. The drawings filed on 12/28/01 are acceptable for examination purposes.

## Claim Rejections - 35 USC § 112

- 3. The following is a quotation of the second paragraph of 35 U.S.C. 112:
  - The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.
- 4. Claims 22-29 are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.
- A. The recited "the sieving component" per claims 22, 28 & 29 constitutes indefinite subject matter as per there being insufficient antecedent basis for this limitation in the claim.
- B) Claims (23-27)/49, ultimately or directly, constitute indefinite subject matter as per said claims being dependent upon non-existent claims, viz., 49, 52 & 53. Furthermore, these claims do not refer to a Preceding Claim. Any further action on the merits, regarding these claims, is herein held in abeyance pending correction.

#### **Double Patenting**

5. The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the "right to exclude" granted by a patent and to prevent possible harassment by multiple assignees. See In re Goodman, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); In re Longi, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); In re Van Ornum, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); In re Vogel, 422 F.2d 438, 164 USPQ 619 (CCPA 1970);and, In re Thorington, 418 F.2d 528, 163 USPQ 644 (CCPA 1969).

A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) may be used to overcome an actual or provisional rejection based on a nonstatutory double patenting ground provided the conflicting application or patent is shown to be commonly owned with this application. See 37 CFR 1.130(b).

Application/Control Number: 10/040,539

**Art Unit: 1713** 

٦

Effective January 1, 1994, a registered attorney or agent of record may sign a terminal disclaimer. A terminal disclaimer signed by the assignee must fully comply with 37 CFR 3.73(b).

- 6. Claims 22, 28 and 29 are rejected under the judicially created doctrine of obviousness-type double patenting as being unpatentable over claims 1-8 of U.S. Patent No. 5,916,426.

  Although the conflicting claims are not identical, they are not patentably distinct from each other because the claims of U.S.'426, drawn to a composition, for separating polynucleotides by capillary electrophoresis, comprising a charge-carrying component, a sieving component and a surface interaction component consisting of one or more uncharged water-soluble silica-adsorbing polymers overlap in scope with the inventive claims drawn to a composition, for separating analytes by capillary electrophoresis, comprising a charge-carrying component and a surface interaction component comprising one or more polymers selected from the group consisting of N,N-disubstituted polyacrylamide and N-substituted polyacrylamide, wherein said N substituents are selected from the group consisting of C1 to C3 alkyl, halo-substituted C1 to C3 alkyl, methoxy-substituted C1 to C3 alkyl, and hydroxyl-substituted C1 to C3 alkyl, wherein the composition does not include a crosslinked polymer gel.
- 7. Claims 22, 28 & 29 are rejected under the judicially created doctrine of obviousness-type double patenting as being unpatentable over claims 1-9 of U.S. Patent No. 6,355,709. Although the conflicting claims are not identical, they are not patentably distinct from each other because the claims of U.S.'709, drawn to a composition, for separating analytes by capillary electrophoresis, comprising a charge-carrying component, a sieving component comprising an uncrosslinked polymer and a surface interaction component consisting of one or more uncharged water-soluble silica-adsorbing polymers overlap in scope with the inventive claims drawn to a composition, for separating analytes by capillary electrophoresis, comprising a charge-carrying component and a surface interaction component comprising one or more polymers selected from the group consisting of N,N-disubstituted polyacrylamide and N-substituted polyacrylamide, wherein said N substituents are selected from the group consisting of C1 to C3 alkyl, halo-substituted C1 to C3 alkyl, methoxy-substituted C1 to C3 alkyl, and

Application/Control Number: 10/040,539

Art Unit: 1713

hydroxyl-substituted C1 to C3 alkyl, wherein the composition does not include a crosslinked polymer gel.

### Conclusion

8. The prior art to Shorr et al(U.S. 5,055,517) and Hooper et al(U.S. 5,569,364), listed on the attached FORM PTO 892, is cited as of being illustrative of the general state of the art.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Judy M. Reddick whose telephone number is (571)272-1110. The examiner can normally be reached on Monday-Friday, 6:30 a.m.-3:00 p.m..

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, David Wu can be reached on (571)272-1114. The fax phone number for the organization where this application or proceeding is assigned is 703-872-9306.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Judy M. Reddick Primary Examiner Art Unit 1713

JMR graft 04/22/04